Sign in Subscribe
Associations

Ionis Pharmaceuticals' CEO Brett P. Monia Receives Lifetime Achievement Award

Strategic Insights

— 1 min read

Brett P. Monia, Ph.D., Ionis' chief executive officer, was awarded the 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society (OTS) for his profound contributions to the field of oligonucleotide therapeutics. Dr. Monia's dedication to education, research, and therapeutic application has set a high standard for the industry, and his establishment and oversight of numerous preclinical and clinical programs have led to the approval of several medicines for serious diseases. As a founding member of the OTS, Dr. Monia has been instrumental in shaping the field and inspiring new and seasoned members.

Key Takeaways:

  • Brett P. Monia, Ph.D. has been awarded the 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society (OTS) for his lasting commitment to oligonucleotide therapeutics.
  • Dr. Monia has published over 250 primary research manuscripts, reviews, and book chapters, and holds over 100 patents, demonstrating his significant contributions to the field.
  • As a founding member of the OTS, Dr. Monia has served as OTS President from 2015-2016, highlighting his leadership and dedication to the society.
  • Under Dr. Monia's supervision, Ionis has developed over 40 oligonucleotide-based medicines for neurological, cardiometabolic, and rare diseases.
  • Dr. Monia has been instrumental in establishing and overseeing numerous preclinical and clinical programs at Ionis, resulting in the approval of multiple medicines for serious diseases.
  • The OTS Lifetime Achievement Award recognizes Dr. Monia's dedication to education, research, and therapeutic application, as well as his commitment to advancing the field of oligonucleotide therapeutics.

Statistics:

  • Over 250 primary research manuscripts, reviews, and book chapters published by Dr. Monia.
  • Over 100 patents held by Dr. Monia.
  • 40+ oligonucleotide-based medicines in development for neurological, cardiometabolic, and rare diseases under Dr. Monia's supervision.
  • Ionis has developed 7 FDA-approved medicines under Dr. Monia's leadership, including the first targeted delivery medicine for a genetic form of amyloidosis and the first RNA-targeted medicine for hereditary angioedema.

Sources:

  • BusinessWire
  • Oligonucleotide Therapeutics Society (OTS)
  • Ionis Pharmaceuticals, Inc.

Read more